ArticleStem cells international2025
ECM Protein CYR61 Promotes Migration and Osteoblastic Differentiation of Irradiation BMSCs via Migrasomes.
Article in Stem cells international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoradionecrosis of the jaw (ORNJ) is a complication of radiation therapy that can lead to hard-to-repair bone defects. Bone marrow mesenchymal stem cells (BMSCs) have been identified as potential "seeds" for restoring bone defects. In this study, we reported extracellular matrix protein cysteine-rich angiogenic inducer 61 (CYR61) to enhance the migratory and osteogenic functions of irradiated BMSCs (IR BMSCs) by migrasomes. Various assays, including alkaline phosphatase (ALP) activity assay, Cell Counting Kit-8 (CCK-8), apoptosis analysis, qRT-PCR, western blot, ALP staining, alizarin red S (ARS) staining, wound healing assay, transwell assay, and co-immunoprecipitation (co-IP) were conducted to assess the optimal radiation dose for generating IR BMSCs and migrasome functionality. Proteomics, bioinformatics analysis, gene transfection, and molecular docking were employed to identify key molecules mediating migration and osteoblastic differentiation and its downstream mechanisms. Furthermore, confocal microscopy, transmission electron microscopy (TEM), and western blot were utilized to identify migrasomes. Results showed that a radiation dose of 2 Gy inhibited migratory and osteogenic abilities of cells without significantly affecting viability. CYR61 emerged as a pivotal molecule regulating BMSC migration and osteoblastic differentiation through binding to integrin αvβ3 at the 125th aspartic acid and activating the ERK signaling pathway. We discovered that migrasomes are the key vehicle effectively delivering CYR61 to restore migration and osteogenesis of IR BMSCs. In conclusion, migrasomes-secreted CYR61 facilitating a promotional effect can regulate the migration and osteogenesis of IR BMSCs. Thus, migrasomes-origin CYR61 may serve as potential therapeutic agents for repairing ORNJ-related bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.